Propylone

Propylone
Clinical data
Other names3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA
Drug classMonoamine releasing agent; Monoamine reuptake inhibitor
Identifiers
  • 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H17NO3
Molar mass235.283 g·mol−1
3D model (JSmol)
  • CCCNC(C)C(=O)C1=CC2=C(C=C1)OCO2
  • InChI=1S/C13H17NO3/c1-3-6-14-9(2)13(15)10-4-5-11-12(7-10)17-8-16-11/h4-5,7,9,14H,3,6,8H2,1-2H3
  • Key:YFVKHKCZBSGZPE-UHFFFAOYSA-N

Propylone, also known as 3,4-methylenedioxy-N-propylcathinone is a mixed monoamine releasing agent and reupake inhibitor of the cathinone family related to methylone and ethylone.[1]

It acts specifically as a weak partial serotonin–dopamine releasing agent (SDRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values for induction of monoamine release of 3,128 nM (30%) for serotonin and 976 nM (20%) for dopamine, and IC50Tooltip half-maximal inhibitory concentration value for monoamine reuptake inhibition of 2,462 nM for serotonin, 28,540 nM for norepinephrine, and 1,863 nM for dopamine.[1]

The drug was first described in the literature in a 1996 patent by Alexander Shulgin and Peyton Jacob III.[2] It was subsequently characterized more thoroughly by 2015[1] and was encountered as a novel designer drug in Europe by 2016.[3][4][5]

See also

References

  1. ^ a b c Sakloth F (11 December 2015). Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action. Theses and Dissertations (Ph.D. thesis). Virginia Commonwealth University. doi:10.25772/AY8R-PW77. Retrieved 24 November 2024 – via VCU Scholars Compass.
  2. ^ WO 1996039133, Jacob III P, Shulgin AT, "Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents.", published 12 December 1996, assigned to Neurobiological Technologies, Inc. 
  3. ^ "EMCDDA–Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA". Europol. 23 October 2018. Retrieved 11 March 2025.
  4. ^ Liu C, Jia W, Li T, Hua Z, Qian Z (August 2017). "Identification and analytical characterization of nine synthetic cathinone derivatives N-ethylhexedrone, 4-Cl-pentedrone, 4-Cl-α-EAPP, propylone, N-ethylnorpentylone, 6-MeO-bk-MDMA, α-PiHP, 4-Cl-α-PHP, and 4-F-α-PHP". Drug Test Anal. 9 (8): 1162–1171. doi:10.1002/dta.2136. PMID 27863142.
  5. ^ Pulver B, Fischmann S, Gallegos A, Christie R (December 2024). "EMCDDA framework and practical guidance for naming cathinones". Drug Test Anal. 16 (12): 1409–1435. doi:10.1002/dta.3662. PMC 11635063. PMID 38389255.
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.